Memory CD4 T cell-derived IL-2 synergizes with viral infection to exacerbate lung inflammation

K. Kai McKinstry

University of Central Florida

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Immunology of Infectious Disease Commons, Immunopathology Commons, Pathological Conditions, Signs and Symptoms Commons, Pathology Commons, and the Virus Diseases Commons

Repository Citation


Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Memory CD4 T cell-derived IL-2 synergizes with viral infection to exacerbate lung inflammation

K. Kai McKinstry¹, Fahmida Alam¹, Valeria Flores-Malavet¹, Mate Z. Nagy¹, Stewart Sell², Andrea M. Cooper³*, Susan L. Swain⁴, Tara M. Strutt¹*

¹ Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, United States of America, ² Department of Health, Wadsworth Center, Albany, New York, United States of America, ³ Trudeau Institute, Saranac Lake, New York, United States of America, ⁴ Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

* Current address: Department of Infection, Immunity, and Inflammation, University of Leicester, Leicester, United Kingdom
* tara.strutt@ucf.edu

Abstract

Defining the most penetrating correlates of protective memory T cells is key for designing improved vaccines and T cell therapies. Here, we evaluate how interleukin (IL-2) production by memory CD4 T cells, a widely held indicator of their protective potential, impacts immune responses against murine influenza A virus (IAV). Unexpectedly, we show that IL-2-deficient memory CD4 T cells are more effective on a per cell basis at combating IAV than wild-type memory cells that produce IL-2. Improved outcomes orchestrated by IL-2-deficient cells include reduced weight loss and improved respiratory function that correlate with reduced levels of a broad array of inflammatory factors in the infected lung. Blocking CD70-CD27 signals to reduce CD4 T cell IL-2 production tempers the inflammation induced by wild-type memory CD4 T cells and improves the outcome of IAV infection in vaccinated mice. Finally, we show that IL-2 administration drives rapid and extremely potent lung inflammation involving NK cells, which can synergize with sublethal IAV infection to promote acute death. These results suggest that IL-2 production is not necessarily an indicator of protective CD4 T cells, and that the lung environment is particularly sensitive to IL-2-induced inflammation during viral infection.

Author summary

We show that memory CD4 T cell mediated protection against influenza A virus is independent of the signature multifunctional cytokine IL-2 that is thought to define the most protective memory cells. IL-2 deficient cells are more effective than wild-type memory cells on a per cell basis at combating IAV and drive tempered early innate inflammatory responses. Our studies define a clear and surprising role for IL-2 as a cytokine adjuvant.
within the lung that can synergize with virus driven acute inflammatory responses to cause morbidity during sublethal respiratory viral infection.

**Introduction**

Interleukin-2 (IL-2) produced by CD4 T cells is thought to be critical for orchestrating optimal immune responses by acting as an autocrine growth and survival factor [1] as well as a paracrine cytokine to enhance the activity of other cell types, notably NK cells and CD8 T cells [2, 3]. IL-2 production by T cells is strictly regulated by antigen recognition and costimulatory signals, resulting in its transient secretion during cognate interactions with activated APC [4]. A distinguishing feature of resting memory and memory-derived secondary CD4 T cell effectors is their ability to produce higher levels of IL-2 more rapidly than naïve and primary CD4 T effector cells [5, 6] and CD8 T cells [7, 8]. Consequently, memory CD4 T cells are the most physiologically relevant source of IL-2 in vivo.

The capacity of Th1-polarized memory cells to co-produce high levels of IL-2 in combination with IFN-γ is widely held as a marker of superior protective capacity [9]. Indeed, memory CD4 T cells marked by dual production of IFN-γ and IL-2 provide robust immunity against influenza A virus (IAV) challenge in murine models [10–12]. Large numbers of memory cells capable of producing IL-2 and responding rapidly against IAV have also been characterized in human lungs [13, 14] and transcriptional signatures, phenotypes, and functional analysis support that lung-resident memory CD4 T cells are strong producers of IL-2 [12, 15]. Importantly, the presence of increased numbers of IAV-specific memory CD4 T cells prior to seasonal infection correlates with improved clinical outcome in human longitudinal studies [16]. Conversely, severe influenza disease has been associated with decreased levels of IL-2 in the lung [17]. These findings support the concept that IL-2 production is essential for optimizing immunity against IAV mediated by memory CD4 T cells. Here, we directly test this hypothesis.

To overcome major technical and physiological barriers that prevent the straightforward investigation of the impact of memory CD4 T cell-derived IL-2 in vivo, we generated memory CD4 T cells specific for IAV in vitro from naïve TcR transgenic precursors in the presence of exogenous IL-2 [5]. This model provides IL-2-dependent signals to IL-2-deficient (Il2−/−) CD4 T cells during priming that are essential to form most CD4 memory populations by programming IL-7 receptor expression and rescuing effector cells from apoptosis [18, 19]. We used WT and Il2−/− memory cells generated in this way in a well-established adoptive transfer model in which naïve host mice are challenged with IAV recognized by the donor cells. This reductionist approach overcomes complications associated with long-term blockade of IL-2 or IL-2 receptors by antibody administration which has off target effects through the disruption of FoxP3+ T regulatory (T reg) function that can independently impact the outcome of infections, including secondary IAV challenge [20]. Additionally, while conditional knock-out models that rely on the targeted expression of cre-recombinase to delete floxed genes are widely employed, the efficiency of inducible knock systems dependent upon tamoxifen-induced cre-recombinase expression can have varied efficiency within different tissues that can confound observations [21].

Unexpectedly, we find that Il2−/− IAV-specific memory CD4 T cells provide superior protection against IAV compared to WT memory cells of the same specificity. Improved outcomes associated with Il2−/− responses include wide-ranging reductions in the constituents of pulmonary and systemic inflammation, accelerated viral clearance, improved pulmonary mechanics,
and reduced weight loss. We also show that blocking the CD70-CD27 costimulatory pathway to dramatically reduce IL-2 production by memory CD4 T cells [19] tempers inflammation and morbidity in an adoptive transfer model as well as in intact vaccinated wildtype mice. Finally, we show that IL-2 administration to naive mice directly and rapidly upregulates a broad array of cytokines and chemokines in the lung and synergistically enhances inflammation induced by IAV, indicating that the lung is particularly sensitive to IL-2-driven inflammation. NK cells are major contributors to pulmonary IL-2-induced inflammation. Moreover, NK cell depletion during IAV challenge of recipients of WT memory CD4 T cells phenocopies the improved outcomes seen in Il2−/− memory CD4 T cell recipients.

Overall, our results indicate that memory CD4 T cell-derived IL-2 acts as a potent adjuvant in the lung that enhances the production of a broad early inflammatory response during acute viral infection. We find that IL-2 synergizes with pathogen-driven stimulation of innate immunity to drive robust inflammatory responses that can worsen outcomes during primary IAV infection as well as in models of memory CD4 T cell-mediated protection against lethal IAV challenge. Our findings have important implications for therapies aimed at reducing the severity of IAV infection, for the correlates of protection used to design and evaluate T cell-based vaccines, and for the consequences of respiratory infection during the clinical use of therapeutics that result in increased levels of IL-2. This work may also help provide mechanistic insight into the immunopathological impact of memory CD4 T cells induced by vaccination in models of chronic infection [22, 23].

Results

Increased levels of IL-2 are detected during heterosubtypic challenge of IAV-primed mice

We previously found that IAV-specific lung-resident memory CD4 T cells generated from naive TcR Tg donor cells displayed robust IL-2 production when assayed at day 30 post-infection and beyond [12]. We used shielding from labeling by i.v. administered anti-CD4 Ab to discriminate lung-resident from circulating CD44hi CD4 T cells in intact IAV-primed mice and found that the shielded cells displayed strong IL-2 production via intracellular cytokine staining following stimulation with PMA and ionomycin (Fig 1A). This confirms that endogenous, polyclonal lung-resident memory CD4 T cells display a strong capacity to produce IL-2. We thus reasoned that IL-2 signals may have a greater impact on immune responses against heterosubtypic IAV infection than during primary responses against IAV where IL-2-producing CD4 T cells only reach the lung in significant numbers at 6 or 7 days post-infection [24]. Indeed, we detected significant levels of IL-2 in the lungs of mice during the first week of heterosubtypic IAV infection while IL-2 was barely detectable during the same timeframe of a primary IAV response (Fig 1B).

In order to access the role of IL-2 production by memory CD4 T cells during their antigenic recall, we used a previously validated model employing WT and Il2−/− TcR transgenic CD4 T cells to generate memory populations from Th1-polarized effector populations in vitro [5]. Importantly, when transferred to naïve adoptive hosts that are then challenged with IAV, these memory cell responses mirror key elements of the endogenous CD4 T cell recall response against IAV [8, 10, 19]. Briefly, we provided exogenous IL-2 to cultures of naïve WT or Il2−/− DO11.10 TcR transgenic cells [25] to program their capacity to form memory [19]. The resulting effectors were cultured in vitro in the absence of antigen and inflammatory signals for 3 days during which they transition to a resting state virtually indistinguishable from long-term memory CD4 T cells generated in vivo [5, 19]. We have used such in vitro-generated
memory cells in adoptive transfer studies to determine key mechanisms of CD4 T cell-mediated protection against IAV [26, 27].

To clearly delineate protective functions of memory CD4 T cells versus those provided by memory CD8 T cells, memory B cells, and other primed populations that would not be feasible to block in intact IAV-primed mice [26], we transferred an equal number of WT or Il2−/− DO11.10 memory cells to unprimed mice then infected with A/PR8-OVAII that contains the OVA323-339 epitope recognized by the DO11.10 TcR. We gave 5x10⁶ memory cells, which results in ~5x10⁵ cells able to respond factoring in a ’10% take’ [28]. As previously discussed [26], this number is in the range of the estimate of the total number of memory CD4 T cells generated by IAV priming in BALB/c mice, as well as in studies analyzing DR-1 “humanized” transgenic mice [29] in which the magnitude of the total HA-specific memory CD4⁺ T cell response detected by ELISPOT assay alone is about 1x10⁶ cells. Given that not all cells are expected to make the cytokines assayed in the ELISPOT, and assuming that the response against HA accounts for 20–50% of the total IAV specific cells [29, 30], a conservative estimate of the total memory CD4 T cell pool is in the range of 2-5x10⁵. The recipient mice were challenged with a lethal (2 LD₅₀) dose of IAV against which 5x10⁶ WT memory CD4 T cells protects [26] in order to test as stringently as possible the role of IL-2 production by the memory CD4 T cells during a protective response.

**Early memory CD4 T cell-enhanced inflammation is tempered in the absence of IL-2**

The earliest protective function of memory CD4 T cells upon cognate recognition of antigen during IAV challenge is to ‘jump-start’ innate inflammatory responses in the lung. This innate inflammatory response leads to marked control of viral titers within 3 days of infection (dpi), is generated independently of Type I and II IFN, TNF, and pathogen associated molecular pattern (PAMP) recognition [31], and is likely driven by resident memory T (T⁺RM) cells. To analyze the role of IL-2 production by memory CD4 T cells in promoting this induction of innate immunity, we assessed pulmonary inflammation in naïve recipients of WT or Il2−/− memory CD4 T cells at 3 dpi with A/PR8-OVAII. As expected from previous studies [31], WT memory CD4 T cells induced significantly higher levels of a broad spectrum of inflammatory cytokines...
and chemokines by 3 dpi compared to control mice not receiving memory cells (represented as dashed lines in graphs) (Fig 2). With the exception of TNF, IL-1α, and CCL5 that were detected at levels comparable to those in hosts with WT memory CD4 T cells, recipients of Il2-/- memory cells displayed markedly reduced levels of the factors analyzed (Fig 2A), the majority of which were nevertheless significantly higher than in control mice. To evaluate how long the inflammatory factors remained reduced in the Il2-/- versus WT memory CD4 T cell recipients, we examined lung levels from 4–7 dpi. TNF, which is itself produced by WT and Il2-/- memory CD4 T cells responding to IAV [19], remained similar. In contrast, IL-1α and
IL-1β were reduced when assessed at day 4 and remained lower through 7 dpi in recipients of Il2−/− memory CD4 T cells (Fig 2B). As no differences are seen in donor memory CD4 T cell numbers or in IFN-γ production at d4 and d7 (Fig 2C–2F), these results suggest that IL-2 production from memory CD4 T cells promotes potent, acute, and broad production of inflammatory factors in the lung of naïve recipient mice. The kinetic timeframe of the memory CD4 T cell-driven enhanced lungs of recipient mice inflammatory response observed here mirrors previous findings and is in line with the response seen in IAV-primed mice post-heterosubtypic challenge [31].

IL-2 from memory CD4 T cells is not required for protection against IAV

The changes seen above could impact the ability of WT versus Il2−/− memory CD4 T cells to protect against infection. To evaluate this, we assessed a number of parameters associated with recovery from IAV challenge including morbidity, mortality, and viral clearance. All naïve recipients of memory CD4 T cells survived, while control mice not receiving memory cells succumbed by 10 dpi (Fig 3A). Strikingly though, recipients of Il2−/− memory CD4 T cells began to recover weight 2–3 days earlier than WT recipients (Fig 3B). The improved kinetics of weight recovery in Il2−/− memory CD4 T cell recipients correlated with modest but significantly accelerated viral clearance at 8 and 10 dpi (Fig 3C). When the number of cells transferred was titrated, the enhanced protective capacity of Il2−/− memory CD4 T cells was even more evident (Fig 3D), supporting the concept that reduced inflammatory responses driven by the memory CD4 T cells in the absence of IL-2 signaling correlate with improved outcomes.

As in previous studies [19], we found no differences between the frequency and proliferation of WT and Il2−/− memory CD4 T cells in the spleen, draining lymph nodes, and lungs on 4 and 7 dpi (S1 Fig), indicating that the enhanced protective capacity of Il2−/− memory CD4 T cells and differences in the inflammatory response observed are not due to differences in the kinetics or peak magnitude of WT versus Il2−/− memory CD4 T cell responses. Similar patterns of improved recovery in recipients of Il2−/− memory cells were seen in nude hosts lacking T cells, JHd hosts lacking B cells, and SCID hosts deficient in both T and B cells (S2 Fig). These observations argue against the possibility that altered helper functions impacting anti-viral B cells or CD8 T cell responses, or altered activity of IL-2 dependent host regulatory T cells impact the differences seen.

We and others previously found significant differences in the pulmonary function of unprotected versus protected animals during the first week of IAV challenge [32–34]. We thus analyzed respiratory mechanics in naïve recipients of WT or Il2−/− memory CD4 T cell and found that recipients of Il2−/− cells demonstrated improved respiratory rates and pulmonary minute volumes from 4 to 5 dpi. On 6 dpi, both groups of memory CD4 T cells recipients began to show signs of recovery in respiratory rates and only minute volumes remained significantly different (Fig 3E). Furthermore, lower levels of serum albumin, a measure of vascular leak, were detected in the bronchoalveolar lavage of Il2−/− versus WT memory CD4 T cell recipients on 5 and 6 dpi (Fig 3F), indicating reduced pulmonary edema. Interestingly, histopathologic analysis of the lung did not reveal marked differences between recipients of WT or Il2−/− cells at 7 dpi (Fig 3G and 3H). Together, these results indicate that early IL-2 production by memory CD4 T cells responding to IAV amplifies inflammatory responses that impair pulmonary function and promote pulmonary edema without causing measurable increases in immunopathology.

Blocking CD70-mediated signaling tempers memory CD4 T cell-dependent inflammation

Given that memory CD4 T cell derived-IL-2 appears to amplify IAV-associated inflammatory responses, modulating IL-2 production may serve as a therapeutic strategy to decrease
morbidity. Treating mice with a blocking antibody against CD70 significantly reduces IL-2 and IFN-γ production from memory CD4 T cells responding in the lung at 7 dpi with IAV (Fig 4A and 4B) but does not impact their response kinetics or ability to control virus [19]. Similar control of IL-2 production from CD4 and CD8 T cells by CD70-dependent signals has been found in other infection models [35, 36]. We thus asked if blocking CD70 as a means to reduce IL-2 production could improve the outcome of WT memory CD4 T cell-mediated protection. Much like the recipients of Il2−/− memory CD4 T cells in Fig 2, recipients of WT
memory CD4 T cells treated with anti-CD70 antibody showed reduced levels of IL-1α, IL-1β, IFN-γ, IL-6, IL-17, CCL2 (MCP-1), CXCL1 (KC), and IL-12 (Fig 4C), many of which are associated with exacerbated IAV infection [37–40]. In contrast to these observations, we previously
found memory CD4 T cell-induced levels of IL-1, IL-6, CCL2, CXCL1, and IL-12 to be similar in WT and IFN-γ-receptor knockout mice following IAV challenge [31], arguing against changes in IFN-γ production by memory CD4 T cells following anti-CD70 antibody treatment contributing to the patterns seen in Fig 4C. Instead, the significantly lower amount of IL-2 in lung homogenates with CD70 blockade (Fig 4D), supports the position that a reduction in the amount of IL-2 available for paracrine signaling plays a major role in the tempered inflammatory responses observed. The reduced inflammatory response and corresponding small but significant reduction in weight loss and faster recovery (Fig 4E) seen with CD70 blockade largely phenocopies observations with Il2−/− memory CD4 T cell transfer in Figs 2 and 3.

To test whether blocking CD70 to reduce memory CD4 T cell-driven inflammation could improve outcomes in a more translational setting, naïve WT mice were primed with a cold-adapted vaccine strain of IAV (A/Alaska; H2N2) and were challenged after 35 days with A/PR8 (H1N1). Groups of primed mice were treated with CD70 blocking antibody or an isotype control only during heterosubtypic A/PR8 infection. Given that memory CD8 T cell responses are largely independent of CD27:CD70 signaling [41] and since they can provide strong protection independently of the CD4 T cell recall response [42], to specifically address the isolated impact of CD4 T cell mediated protection IAV-primed mice were also depleted of CD8 T cells prior to heterosubtypic challenge. All primed mice survived and CD70 blockade improved the time to recovery of the mice by 2–3 days (Fig 4F). In contrast to CD70 blockade as well as treatment with IL-2 neutralizing antibodies, administration of exogenous IL-2 to mice challenged with IAV failed to improve recovery (Fig 4G). These findings suggest that the protective efficacy of vaccine-primed memory CD4 T cells can be improved by reducing their IL-2 production.

**IL-2 directly drives broad lung inflammation that synergizes with viral infection**

Our results imply that the improved protective efficacy of the Il2−/− memory CD4 T cells in the adoptive transfer model employed here is due largely to differences in the inflammatory response generated upon infection. IL-2 is known to activate innate and adaptive immune cells such as NK cells and CD8 T cells but also drives T reg responses that have anti-inflammatory actions [43]. Though administration of IL-2 has been reported to promote systemic inflammation and febrile illness in cancer patients [44], detailed analysis of how IL-2 impacts the lung environment is lacking. We thus analyzed whether providing IL-2 in the absence of memory CD4 T cell transfer would directly enhance inflammatory cytokine and chemokine expression in the lung, even in the absence of IAV infection.

We first administered soluble IL-2 or IL-2:anti-IL-2 antibody (clone S4B6) complexes (IL-2C) [45–47] to unmanipulated mice by i.p. injection for 3 consecutive days and analyzed lung homogenates and serum for changes in cytokine and chemokine expression. We previously found that this regime, employing 2 μg of IL-2, restored memory CD4 T cell generation from Il2−/− CD4 T cells to WT levels in an IAV model, indicating its ability to deliver physiologically relevant IL-2 signals in vivo [19]. Strikingly, IL-2C treatment drove strong expression of a number of analytes such as IL-6, IFN-γ, IL-17, and G-CSF (S3A Fig) detected in Fig 2, particularly in the lung and to a lesser extent in the serum.

The inflammatory factors seen in the lung following systemic IL-2 administration could originate from other sites. However, when compared to the response seen with i.p. administration, an even more robust response was seen in the lung when IL-2C was administered intra-nasally (Fig 5A). This supports the conclusion that beyond the known ability of IL-2 to stimulate vascular leak and pulmonary edema [46, 48], the lung environment is extremely sensitive to rapid IL-2-dependent induction of inflammatory cytokines and chemokines, even in...
the absence of infection. As the 2 μg dose of IL-2 may deliver sustained IL-2 signaling not typically achieved during immune responses, we titrated the amount of IL-2 used. The pro-inflammatory impact of the IL-2C was proportional to the dose administered, with significant pro-inflammatory effects in analytes such as CCL2 arising with even 0.5 μg of IL-2 and broad effects seen at 1 μg. The impact of the IL-2C was abrogated by pre-treating hosts with blocking antibody against CD122 (S3B Fig), confirming that IL-2 itself rather than potential contaminants in reagents was responsible for the inflammatory impact.

In agreement with previous observations [45], IL-2 and IL-2C treatment also caused the expansion of several major leukocyte populations in the spleen (S3C Fig). Some of these patterns were also seen in the lung. In particular, IL-2C treatment dramatically expanded NK cells and to a lesser extent CD8 and CD4 T cells as well as inflammatory CD45+ MHC-II+ CD11b + Ly6C+ APC [49] (S3C and S3D Fig). Given the dramatic effect of IL-2C administration on the lung environment, we assessed pulmonary mechanics in uninfected animals receiving IL-2C. When compared to untreated controls, the IL-2C-driven inflammatory response correlated with decreased respiratory function (Fig 5B).
We next tested whether and how IL-2 impacts the outcome of primary IAV infection by treating unprimed WT mice with IL-2C for the first 3 days of a 0.2 LD\textsubscript{50} A/PR8-OVA\textsubscript{II} challenge. Infected mice also treated with IL-2C displayed higher levels of a broad array of cytokines and chemokines in the lung compared to mice only infected with IAV or mice only treated with IL-2C (Fig 6A), indicating strong synergy between infection-induced and IL-2-dependent inflammatory pathways. However, histopathological changes were not appreciably enhanced in mice receiving IAV and IL-2C versus mice treated with only IAV or only with IL-2C (Fig 6B and S4 Fig), agreeing with the lack of histological changes in recipients of WT or Il2\textsuperscript{-/-} memory CD4 T cells following IAV infection (Fig 3). Nevertheless, IL-2C treatment for 4 instead of 3 days resulted in acute death of infected mice, even when lower amounts of IL-2 were used (Fig 6C). In marked contrast, when IL-2C treatment was initiated at later time-points (5 to 9 dpi) that coincide with the onset of viral clearance, all mice survived (Fig 6D). Thus, IL-2 signals delivered early but not at later timepoints of infection when T cell effectors reach their peak, potently enhance acute IAV-induced recruitment and/or activation of inflammatory cells in the lung and transform a mild illness to a fatal infection.

Fig 6. Early IL-2 synergizes with IAV to drive lethal inflammatory responses. Uninfect ed and sublethal 0.2 LD\textsubscript{50} A/PR8-OVA\textsubscript{II} infected BALB/c mice were treated with PBS or IL-2Cs containing 2 \( \mu \)g of IL-2 for 3 days. On day 4, inflammatory responses in lung homogenates were measured. The levels of cytokines and chemokines detected are shown in (a) (3 mice per group; 1 of 3 experiments). The dashed line in bar graphs represents the level of analyte detected with IL-2C treatment alone. In separate experiments, lungs were evaluated blindly and scored for inflammation in the bronchi, blood vessels, and alveoli (b). IL-2C treatment with the indicated amount of IL-2 was extended to 4 days (c) or given on the indicated days (d) and mortality monitored (3–5 mice per group; 1 of 3 experiments). All error bars represent the standard deviation, and * \( P < 0.05 \), ** \( P < 0.001 \), *** \( P < 0.0001 \).
IL-2 induced NK cells are major contributors of lung inflammation and fatal outcomes

Since NK cells and neutrophils were enhanced by IL-2C, and are prominently involved in driving IL-2-dependent vascular leak [50, 51], we determined their involvement in the IL-2-induced inflammatory response. We first characterized the dynamics of NK and neutrophil responses in the lung at 3 dpi in naïve recipients of WT or Il2/− memory CD4 T cells, or in controls not receiving cell transfer. While total numbers of NK cells in both WT or Il2/− memory CD4 T cell recipients were similar, significantly more activated (CD44hi and IFN-γ+) NK cells were detected in WT memory CD4 T cell recipients (Fig 7A). No differences in total neutrophil number or activation (SSChi CD69hi) were seen (Fig 7B). Significantly more activated NK cells were also detected at 4 dpi in isotype antibody-treated recipients of WT memory CD4 T cells than in recipients treated with CD70 blocking antibody (Fig 7C), in which reduced levels of paracrine IL-2 are detected (Fig 4B).

We next evaluated the ability of lung-resident memory CD4 T cells isolated from IAV-primed mice to modulate NK cell responses in the presence and absence of IL-2 neutralizing antibody to ensure that the observations made with in vitro-primed memory populations accurately recapitulate elements of the IAV-primed responses. Polyclonal IAV-primed lung-resident memory CD4 T cells were transferred intranasally to naïve recipients as previously described [12] and lung NK cell responses following IAV infection analyzed on 4 dpi. Both the number of total NK cells as well and activated NK cells were reduced when IL-2 was neutralized in lung-resident memory CD4 T cell recipients (Fig 7D), mirroring findings obtained with in vitro-primed memory CD4 T cells.

Finally, we tested whether memory CD4 T cell-derived IL-2 could impact NK cell responses in lungs imprinted by prior IAV infection [52] rather than in the models above assessing memory CD4 T cell responses in otherwise naïve mice. We transferred WT memory CD4 T cells to naïve hosts and primed with IAV. At 60 dpi, cognate peptide was administered intranasally to recall the donor CD4 T cells in the lung [31]. We analyzed lung NK cells 4 days after peptide administration in mice treated with isotype or IL-2 neutralizing antibodies and found a reduction in activated, but not total NK cells in the absence of IL-2 signaling (S5 Fig). Thus, using multiple approaches, we find that IL-2 production from memory CD4 T cells following TcR stimulation significantly impacts the acute activation profile of NK cells in the lung.

Given the results above and observations that NK cells can maximize neutrophil responses in vivo [53], we next depleted NK cells in naïve mice receiving WT memory CD4 T cell prior to IAV challenge to determine whether and how NK cells impact the outcome of infection. NK cell depletion resulted in reduced weight loss and earlier recovery (Fig 8A and 8B), phenocopying the improved outcomes seen in Il2/− versus WT memory CD4 T recipients depicted in Fig 3, as well that of animals treated with CD70 blocking antibody in Fig 4. Even though they are known to contribute to IL-2 driven vascular leak, additional depletion of neutrophils did not appreciably alter the course of IAV infection (Fig 8A and 8C).

The involvement of NK cells in hampering CD4 T cell memory mediated protection prompted us to determine the extent to which IL-2-induced NK cell responses directly contribute to the production of acute inflammatory factors. To directly test this, we depleted NK cells prior to treating naïve mice with IL-2C and measured inflammatory cytokines and chemokines in the lungs. NK cell depletion resulted in reduced weight loss and earlier recovery (Fig 8A and 8B), phenocopying the improved outcomes seen in Il2/− versus WT memory CD4 T recipients depicted in Fig 3, as well that of animals treated with CD70 blocking antibody in Fig 4. Even though they are known to contribute to IL-2 driven vascular leak, additional depletion of neutrophils did not appreciably alter the course of IAV infection (Fig 8A and 8C).

The involvement of NK cells in hampering CD4 T cell memory mediated protection prompted us to determine the extent to which IL-2-induced NK cell responses directly contribute to the production of acute inflammatory factors. To directly test this, we depleted NK cells prior to treating naïve mice with IL-2C and measured inflammatory cytokines and chemokines in the lungs. NK cell depletion decreased levels of all cytokines and chemokines enhanced by IL-2C treatment during IAV infection (Fig 8D), demonstrating the IL-2-dependent ability of NK cells to markedly shape acute pulmonary inflammation. Finally, to firmly establish a detrimental role for IL-2-driven NK cell responses in the lung during IAV infection, we depleted NK cells in naïve mice prior to IL-2C administration and sublethal IAV challenge.
Remarkably, NK cell depletion protected IAV-challenged WT and *Rag2*−/− mice from acute IL-2C-dependent death (Fig 8E).

In summary, our results using both reductionist models and analysis of intact mice responding to IAV strongly suggest that IL-2 produced by memory CD4 T cells can drive enhanced inflammatory responses in the lung. A major mechanism involved in driving this response is the IL-2-dependent promotion of early NK cell activity that can detrimentally impact the resolution of IAV challenge.

**Discussion**

Defining the most incisive correlates of protective memory T cells in a disease-specific manner is critical to improve monitoring of clinical responses and to promote tailored attributes of T cells induced by vaccination. Fully understanding the impact of tissue environments on the outcome of memory T cell recall is equally important but is poorly understood. Here, we show that during memory CD4 T cell-mediated protective immune responses against IAV, their IL-2 production induces enhanced proinflammatory cytokine production and NK cell responses leading to delayed recovery and compromised lung function. Welsh and collaborators have noted the rheostat nature of NK cell function after viral infection and the pathogenic impact of too many NK cells during medium and high dose LCMV infection [54]. In the setting of IAV, the beneficial versus detrimental impact of NK cells and neutrophil responses remains controversial [55, 56]. Our results suggest that the relative amount of IL-2 available during the early...
phases of the immune response can be an important contextual determinant in regulating the positive versus negative impact of these innate subsets.

Our findings suggest that, at least in the case of IAV infection, the ability of memory CD4 T cells to produce high levels of IL-2 in conjunction with IFN-γ cannot alone be taken as an indicator of superior protective potential. They do not, however, necessarily contradict the general concept that multi-cytokine-producing Th1 memory cells are more protective than cells only able to secrete IFN-γ [57]. Indeed, polyfunctional memory CD4 T cells express a unique molecular signature compared to single IFN-γ producers [58]. Moreover, there are very few differences in the transcriptome of wild-type and IL-2-deficient memory CD4 T cells responding against IAV [15]. These observations support the concept that key protective molecular signatures of multi-functional CD4 memory may be independent of IL-2 expression during
antigenic recall, and as we have shown, IL-2 may instead have its positive activity primarily at
the effector stage to promote CD4 T cell memory generation [19].

Although we observed similar impacts using TcR transgenic and polyclonal CD4 T cells, a
comprehensive understanding of how and when IL-2 produced by CD4 T cell populations
impacts infection requires further study. For example, CD4 T cells with different TcR specifici-
ties have been shown to produce different amounts of IL-2 upon restimulation with cognate
IAV peptides [59], and both higher doses of antigen and higher avidity T cell responses lead to
greater IL-2 production [60]. These findings indicate that responses against certain antigens
may be more or less impacted by the mechanisms described here. Furthermore, optimal CD4
T cell-mediated IAV clearance requires synergy between many different specialized subsets
[61–63]. Whether IL-2 from subsets other than Th1-like cells similarly impacts recall against
IAV requires exploration, but we stress that the majority of CD4 T cells responding to IAV fit
general Th1-like criteria.

Additional studies are also required to determine if IL-2 production from memory CD4 T
cells similarly impacts responses against other pathogens, as well as in other tissues. Adjuvant
effects following IL-2 administration observed during systemic viral infection support that
memory CD4 T cell-derived IL-2 may have similar proinflammatory effects in this setting
[64]. However, that we found a stronger impact of IL-2 on inflammation in the lung than in
the serum, even when IL-2 was administered systemically, suggests the lung and responses
against respiratory infections may be particularly sensitive to IL-2. Indeed earlier studies
found exogenous IL-2 administration to cause cellular proliferation only in specific tissues,
including the lung [65]. We speculate that IL-2 production from vaccine-induced memory
CD4 T cells may in some cases be a component of their immunopathological impact, such as
that observed during chronic LCMV infection [22].

We previously found that blocking CD70 during IAV priming dramatically decreased the
number of memory CD4 T cells formed [19]. The impact on memory generation was due to a
reduction of CD27-dependent autocrine IL-2 production induced by cognate interactions
with CD70+ dendritic cells. Here, we found CD70 blockade to reduce inflammation driven by
memory CD4 T cells responding to IAV. Interestingly, CD70 blockade significantly decreased
IL-2 production as well as IFN-γ production by memory CD4 T cells. While higher levels of
IFN-γ have been implicated in increasing susceptibility to primary IAV infection [66], we have
shown that IFN-γ signaling does not significantly impact the ability of memory CD4 T cells to
drive protective inflammatory responses against IAV [26, 31]. Thus, while we cannot formally
rule out that changes in IFN-γ and other factors have no impact on the improved responses
seen with blocking CD70, our data strongly supports the hypothesis that changes in IL-2 produc-
tion play a central role in this process. Collectively, our observations suggest that the
CD27-CD70 pathway may be targeted as a temporal rheostat to modulate CD4 T cell immu-
nity: during priming, targeting the CD70-CD27 pathway to enhance IL-2 production can
serve to boost the efficiency of memory generation, while early during recall, blocking this
pathway may help to restrain IL-2-driven inflammation originating from memory CD4 T

cells.

Given the potent and broad-ranging proinflammatory activity of IL-2, we predict that
mechanisms must be in place to limit its impact. The lung may be particularly sensitive to IL-
2-driven inflammation because of endothelial cell expression of functional IL-2 receptors [46].
We found previously that while CD4 T cell effectors responding to IAV in the spleen and
draining lymph nodes produce high levels of IL-2, only about 10% of cells responding in the
lung at the peak of the anti-viral response demonstrate robust IL-2 production [10]. This is in
stark contrast to the strong IL-2 production potential observed from CD4 T cells that develops
in the lungs only after the clearance of virus as well as at memory timepoints [12, 67, 68]. We
propose that these findings reflect two distinct kinds of control on IL-2 production by CD4 T cells. First, control of T cell cytokine production appears to be an inherent property of the lung environment [69], which may serve to buffer against IL-2-induced inflammation to maintain maximal pulmonary function. Second, further controls on IL-2 production are likely induced by infection. For example, PDL-1, which dramatically impedes IL-2 production by activated T cells upon ligation of PD-1 [70, 71], is strongly upregulated in the lung early in the course of IAV infection [72, 73]. The extent to which the capacity of lung IAV-specific CD4 T cells to produce high levels of IL-2 during the transition to memory following viral clearance [67] is resultant from downmodulation of inhibitory molecules such as PDL-1 versus CD4 T cell-intrinsic mechanisms warrants further study. Interestingly, IL-2 production by CD4 T cells is needed to promote production of the anti-inflammatory cytokine IL-10 by CD8 T cells responding to IAV [74], which make little of their own IL-2 during heterosubtypic responses [8]. IL-10+ CD8 T cells protect mice against lethal IAV-induced inflammation in some [75] but not other [32] models. Induction of IL-10+ CD8 T cells by CD4 T cell-derived IL-2 may thus act as further layer of buffering against damaging inflammation during respiratory infections. The impact of these restraining mechanisms likely lessens following pathogen clearance.

Therapeutic delivery of IL-2, such as by systemic IL-2C treatment using the S4B6 clone and 1–2 μg of recombinant IL-2 has seen increasing use in experimental models to modulate CD8 T cell and NK cell populations in vivo to improve responses against pathogens and cancers [43]. Our results stress the importance of careful evaluation of how these treatment regimens impact inflammatory environments when interpreting experimental outcomes. Furthermore, we stress that while IL-2 production can be boosted or restored by the systemic blockade of checkpoint inhibitors [76, 77], how production of IL-2 by T cells responding to respiratory infection impacts patient outcome in such settings, including cancer therapy, remains to be determined. Our results argue the clinical use of IL-2 and engineered IL-2 and IL-15 [78] should be viewed with caution, given the fatal outcomes observed when IL-2C treatment synergized with mild, low-dose, IAV infection.

Methods

Ethics statement

Experimental animal procedures were conducted in accordance with guidelines outlined by the Office of Laboratory Animal Welfare (OLAW), National Institute of Health, USA. Protocols were approved by the Animal Care and Use Committee at Trudeau Institute (Saranac Lake, NY) protocol 00–33, the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School (Worcester, MA) protocol A-2198, and the University of Central Florida (Orlando, FL) protocol 18–30.

Mice

Naïve CD4+ T cells were obtained from 5 to 8-week-old male or female DO11.10 Thy1.2/Thy1.1 and l22/Do11.10 Thy1.2/Thy1.1 mice originally provided by A. Abbas (UCSF). Recipients of cell transfers were male BALB/c.Thy1.2 or BALB/c.Thy1.1, nude, JjD, or SCID mice that were at least 8 weeks old. In some experiments, naïve CD4 T cells were obtained from 5 to 8-week-old male OT-II Thy1.2/1.1 mice and C57BL/6 and Rag2/- male recipients were used. Nude, Rag2/-, JjD, and SCID mice were purchased Charles River, Taconic, or Jackson Laboratories. All other mice were obtained from Jackson Laboratories or the breeding facility at Trudeau Institute, the University of Massachusetts Medical School, or the University of Central Florida.
CD4 T cell isolation and in vitro-primed memory generation

Naïve CD4+ T cells were obtained from pooled spleen and peripheral lymph nodes as previously described [24]. Briefly, cells were purified by nylon wool and percoll density gradient separation. CD4 T cells were isolated by positive CD4 MACS selection (Miltenyi). Resulting CD4+ cells routinely expressed a characteristic naive phenotype (small size, CD62Lhi, CD44lo and CD25lo) >97% TcR+. Th1-polarized effectors were generated in vitro as described [5]. Briefly, naïve WT or II2−/− CD4 T cells were cultured with an equal number of irradiated APC (2x10^5 per mL) in the presence of exogenous IL-2 (20 ng per mL), 2 ng per mL IL-12 (Pepro-tech), 10 μg per mL anti-IL-4 antibody (11B11; Bioxcell), and 5 μM OVAII peptide. In vitro-primed memory cells were obtained by thoroughly washing effector cultures at 4 days and reculturing the cells in fresh media for at least 3 days in the absence of Ag and exogenous cytokines. Live cells were isolated by Lympholyte separation (Cedarlane). All donor CD4 T cells were adoptively transferred in 200 μl phosphate buffered saline (PBS) by intravenous (i.v.) injection. A number of donor cells previously determined to protect against lethal IAV infection, 5 x 10^6, was transferred. In some experiments, donor CD4 T cells were labeled with CFSE, as previously described [10], prior to adoptive transfer to monitor in vivo proliferation. In some experiments, lung resident memory CD4 T cells were isolated from IAV-primed mice and 1 x 10^6 adoptively transferred to recipient mice through the intranasal route as previously described [12].

Virus stocks and infections

Influenza A/Puerto Rico/8/1934 (PR8) (H1N1) originating from stocks prepared at the Trudeau Institute and in use in experiments since 1997, A/PR8-OVAII (H1N1) from stock obtained from P. Doherty at St Jude’s Children’s Hospital [79], and the cold-adapted attenuated strain A/Alaska/6/1977 CR-29, (H3N2) virus kindly provided by S. Epstein, NIH were produced in the allantoic cavity of embryonated hen eggs at the Trudeau Institute and the lethal dose (LD₅₀), egg infective dose (EID₅₀) or tissue culture infective dose (TCID₅₀) characterized. Mice were infected intranasally under light isoflurane anesthesia (Webster Veterinary Supply) with the indicated doses of virus in 50 μl PBS and morbidity and mortality monitored. Donor cell injection and viral infection occurred on the same day. In some experiments, 5 μg of cognate peptide was administered intranasally to mice that had received donor memory CD4 T cells and IAV primed 60 days prior. The recovery day, or the day when animals began to regain weight following infection, was also determined.

Detection of IAV titer

Pulmonary viral titer was determined by quantitation of viral RNA. RNA was prepared from whole lung homogenates using TRIzol (Sigma-Aldrich), and 2.5 μg of RNA was reverse transcribed into cDNA using random hexamer primers and Superscript II Reverse Transcriptase (Invitrogen). Quantitative PCR was performed to amplify the acidic polymerase (PA) gene of A/PR8-OVAII using an ABI Prism 7700 Sequence Detector (Applied Biosystems) with 50 ng of cDNA per reaction and the following primers and probe: forward primer, 5’-CGGTCAATACTGCTGA-3’; reverse primer, 5’CATTGGGTTCCTTCCATCCA-3’; probe, 5’-6-FAM-CCAAGTCATGAAGGAGAGGGAATACCGCT-3’. Data were analyzed with Sequence Detector v1.7a (Applied Biosystems). The copy number of the PA gene per 50 ng of cDNA was calculated using a PA-containing plasmid of known concentration as a standard. The number of copies of PA gene per lung is presented.
Cytokine complex, receptor blockade, and depleting antibody treatments

Mice were treated for the indicated days with injections of cytokine or cytokine: anti-cytokine monoclonal antibody complexes. For IL-2 complexes (IL-2C), mice received 2 μg per day of recombinant IL-2 (eBioscience) premixed with 20 μg of anti-mouse IL-2 monoclonal antibody clone S4B6-1 (S4B6) (BD Pharmingen). In certain experiments, the amount of IL-2 in the complexes was varied, as indicated. Complexes were incubated at room temperature for 20 minutes (min.) before intraperitoneal (i.p.) injection in 200 μL of PBS. IL-2C in 50 μL of PBS were also administered intranasally (i.n.). When IL-2 was administered as free cytokine, animals were treated with 20 μg per day in 200 μL of PBS injected i.p.

For some experiments, mice were treated as indicated with 0.25 mg per day of anti-CD122 (IL-2 Rβ) antibody (SH4) to block IL-2 signaling, 0.25 mg per day anti-IL-2 antibodies (S4B6 and JES6-1A12) to neutralize IL-2, 0.5 mg per day of anti-CD70 antibody (FR-70) to block CD70 signaling, 0.25 mg per day of anti-NK1.1 (PK136) to deplete NK cells, 0.5 mg of anti-Ly-6G Ab to deplete neutrophils (1A8), or with appropriate isotype control antibody (all Bioxcell). Antibody was delivered by i.p. injection in 200 μL of PBS.

Tissue preparation and flow cytometry

At different time points after virus infection, blood and lungs were obtained from euthanized animals for Luminex multiplex analysis. Lungs were harvested and homogenized in RPMI 1640 media supplemented with 2mM L-glutamine, 100 IU penicillin, 100 μg/mL streptomycin (Invitrogen), 10 mM HEPES (Research Organics), 50 μM 2-mercaptoethanol (Sigma-Aldrich) and 7.5% fetal bovine serum (Hyclone) and serum collected from blood.

Alternatively, for flow cytometry, mice were euthanized by cervical dislocation followed by exsanguination by perforation of the abdominal aorta. Lungs were perfused by injecting 10 ml of PBS in the left ventricle of the heart. Lungs and spleen were prepared into single cell suspensions by mechanical disruption of organs and passage through a nylon membrane. Flow cytometry was performed as previously described [24] using fluorochrome-labeled antibodies at manufacturer’s recommended dilutions for surface staining including anti-Thy1.1 (OX-7), anti-Thy1.2 (53–2.1), anti-CD4 (RM4.5 and GK1.5), anti-CD8 (53–6.7), anti-CD45.2 (104), anti-γδ TcR (GL3), anti-β TCR (H57-597), anti-CD3 (17A2), anti-CD49d (R1-2), anti-CD25 (PC61), anti-CD44 (1M7.8.1), anti-CD69 (H1.2F3), anti-CD11b (M1/70), anti-Gr-1 (RB6-8C5), anti-MHC-II (M5/114.15.2), and anti-Ly6C (HK1.4). In some experiments, tissue resident memory CD4 T cells were identified by intravenous administration of 3 μg of fluorochrome-labeled antibody 3 minutes prior to euthanasia and tissue harvest [12]. Intracellular cytokine staining was performed as previously described [19]. Briefly, cells were treated with PMA and Ionomycin for 4 hours or stimulated overnight with cognate peptide presented by APC, with Brefeldin A added after 2 h. Cells were then surface stained, fixed for 20 min. in 4% paraformaldehyde, and permeabilized by 10 min. incubation in 0.1% saponin before staining for cytokine by the addition of anti-IFN-γ and anti-IL-2 fluorescently labeled antibodies. Analysis was performed using FACS Canto II and LSRII instruments (BD Biosciences) and FlowJo (Tree Star) analysis software.

Detection of inflammatory cytokines and chemokines and BAL albumin

Levels of cytokines and chemokines in lung homogenates or serum were determined using mouse multiplex kits (Invitrogen and Millipore) read on a Bio-Plex Multiplex 200 Luminex reader (Bio-Rad). Levels of serum albumin in the BAL fluid were determined using a Mouse Albumin ELISA Quantification Kit as per manufacturer’s instructions (Bethyl Laboratories Inc.).
**Histology**

For assessment of immunopathology following viral infection and IL-2C treatment, lungs lobes were isolated and immediately fixed in 10% neutral buffered formalin. Lung samples were subsequently processed, embedded in paraffin, sectioned, placed on L-lysine-coated slides, and stained with Hematoxylin and Eosin (H&E) using standard histological techniques. Sections were graded blindly from 0 to 4, for the extent of inflammatory cell infiltration and damage of bronchi, arteries or alveoli by a certified pathologist (S. Sell).

**Measurement of pulmonary mechanics**

Non-invasive whole-body plethysmography (WBP) (Buxco) was employed to measure respiratory rates (breaths/min.), minute volumes (mL/min.), and enhanced pause PenH, on conscious, unrestrained animals following IAV infection and IL-2C treatment. The minute volume is defined as the volume of air exchanged during a 1-min. interval and is calculated as follows [respiratory rate X tidal volume].

**Statistical analysis**

Group sizes of \( n = 3 \) to 15 were employed. Unpaired, two-tailed, Students \( t \)-tests, \( \alpha = 0.05 \), were used to assess whether the means of two normally distributed groups differed significantly. One-way ANOVA analysis with Bonferroni’s multiple comparison post-test was employed to compare multiple means. Two-way ANOVA analysis with repeated measures was also employed in some experiments. The Log Rank test was used to test for significant differences in Kaplan-Meier survival curves. All error bars represent the standard deviation. Significance is indicated as * \( P < 0.05 \), ** \( P < 0.005 \), *** \( P < 0.001 \), **** \( P < 0.0001 \).

**Supporting information**

S1 Fig. Engraftment and response of WT and \( I\ell_2^{-/-} \) memory CD4 cells in congenic adoptive transfer recipients. Unprimed BALB/c recipients of WT or \( I\ell_2^{-/-} \) memory DO11.10 CD4 T cells were challenged with a 2 LD\(_{50}\) dose of A/PR8-OVA\(_{II}\) virus. On indicated days, engraftment and expansion of donor cells was assessed in spleens, draining lymph nodes (dLN), and lungs of recipient mice. Representative donor cell expression of the congenic marker and CD4 on gated lymphocytes is shown in (a) and donor cell expansion via loss of CFSE shown in (b). Percentages represent the frequency of donors among total lymphocytes (3–5 mice per group; 1 of 3 experiments).

(EPS)

S2 Fig. IL-2 production is not needed for IAV-specific memory CD4 T cell-mediated protection in T and B cell deficient hosts. The indicated unprimed immunodeficient recipient hosts received WT or \( I\ell_2^{-/-} \) memory DO11.10 CD4 T cells and were challenged with a 2500 EID\(_{50}\) dose of A/PR8-OVA\(_{II}\) virus. Morbidity was monitored (3–5 mice per group; 1 of 3 experiments). All error bars represent the standard deviation and * \( P < 0.05 \).

(EPS)

S3 Fig. IL-2 drives potent inflammatory responses in the lung. Naive BALB/c mice were treated with PBS, 20 \( \mu \)g of IL-2, or IL-2Cs containing 2 \( \mu \)g of IL-2 for 3 days. On day 4, inflammatory responses in lung homogenates and serum were measured (a) (summary from 3 experiments containing 3 mice per group). In separate experiments, mice were treated with IL-2C containing the indicated amount of IL-2 without or with anti-CD122 antibody to block the IL-2R. Inflammatory responses in lung homogenates were measured on d4 (b) (3 mice per group;
1 of 2 experiments). Lymphocyte populations in the spleen and lung of IL-2 or IL-2C treated animals were enumerated and compared to control mice (e). The frequency of inflammatory CD45+ MHC-II+ CD11b+ Ly6C+ APC were also determined in the lung of mice treated with IL-2C or PBS alone (d). All error bars represent the standard deviation, and * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

**S4 Fig.** IL-2 contributes to alveolar and perivascular histopathology. Uninfected and low-dose, sublethal 0.2 LD50 A/PR8-OVAII infected BALB/c mice were treated with PBS or IL-2Cs containing 2 μg of IL-2 for 3 days. Representative photomicrographs of H & E stained tissue sections of lungs on 4 dpi are shown, Br: bronchus; Ar: artery.

**S5 Fig.** Memory CD4 T cell derived IL-2 induces NK cell activation in IAV primed environments. Unprimed BALB/c hosts received WT memory CD4 T cells and were infected with 0.5 LD50 A/PR8-OVAII virus. On day 60 and 62 post priming, 5 μg of cognate peptide was administered and total numbers and activated NK cells assessed by flow cytometry (4 mice per group) and * P < 0.05.

**Acknowledgments**

Trudeau Institute Inc., the University of Massachusetts Medical School, and the University of Central Florida College of Medicine provided technical support for this work.

**Author Contributions**

**Conceptualization:** K. Kai McKinstry, Susan L. Swain, Tara M. Strutt.

**Data curation:** Fahmida Alam, Valeria Flores-Malavet.

**Formal analysis:** K. Kai McKinstry, Valeria Flores-Malavet, Mate Z. Nagy, Stewart Sell, Andrea M. Cooper, Tara M. Strutt.

**Funding acquisition:** K. Kai McKinstry, Susan L. Swain, Tara M. Strutt.

**Investigation:** K. Kai McKinstry, Fahmida Alam, Valeria Flores-Malavet, Mate Z. Nagy, Stewart Sell, Tara M. Strutt.

**Methodology:** K. Kai McKinstry, Tara M. Strutt.

**Project administration:** K. Kai McKinstry, Andrea M. Cooper, Susan L. Swain, Tara M. Strutt.

**Resources:** K. Kai McKinstry, Stewart Sell, Andrea M. Cooper, Susan L. Swain, Tara M. Strutt.

**Supervision:** K. Kai McKinstry, Andrea M. Cooper, Susan L. Swain, Tara M. Strutt.

**Validation:** K. Kai McKinstry, Fahmida Alam, Valeria Flores-Malavet, Mate Z. Nagy, Tara M. Strutt.

**Visualization:** K. Kai McKinstry, Mate Z. Nagy, Stewart Sell, Tara M. Strutt.

**Writing – original draft:** K. Kai McKinstry, Susan L. Swain, Tara M. Strutt.

**Writing – review & editing:** K. Kai McKinstry, Fahmida Alam, Valeria Flores-Malavet, Mate Z. Nagy, Stewart Sell, Andrea M. Cooper, Susan L. Swain, Tara M. Strutt.
References


